4.12.22-Health-Science-Parisa-Yousefpour

• Video details

  Self-replicating RNAs termed replicons have begun to be explored as a promising platform technology for vaccines and gene therapy.  Upon delivery to host cells, the replicon copies itself and therefore, allows for prolonged and increased transgene expression with a small initial dose.  We employ the replicon platform for 1) vaccine development for sustained antigen expression coupled with the intrinsic adjuvanticity of replicons, and 2) cancer immunotherapy to stimulate multiple synergistic pathways of antitumor immunity. In addition, harnessing synthetic biology tools, we are developing next generation replicon platforms that incorporate microRNA-based classifier and small-molecule responsive gene circuits for internal and external regulation of transgene expression, respectively.  Our recent advances and directions on gene delivery with replicons will be presented and discussed.

Locked Interactive transcript